BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

Alnylam Pharmaceutical’s has secured US Food and Drug Administration (FDA) approval for Amvuttra (vutrisiran), expanding its ...

Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA interference approach can set it apart from its peers. | Despite growing competition ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

The FDA has approved a supplemental new drug application for the treatment of cardiomyopathy wild-type or hereditary ...

Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...